RECELL GO Demonstrates Successful First Clinical Use in UK Burn Surgery, Supporting Global Adoption of Automated Autologous Cell Therapy
核心洞察
AVITA Medical presented the first UK clinical experience with RECELL GO (搜索) at the 2026 British Burn Association Annual Meeting, detailing outcomes from 17 patients treated at Stoke Mandeville Hospital.
All patients achieved uncomplicated donor-site healing, complete graft take, and successful discharge without complications, with the automated system demonstrating reduced procedural variability and improved operating room efficiency.
RECELL GO (搜索) combines a reusable processing device with a single-use preparation kit to standardize autologous cell harvesting at the point of care, and has received CE-marking in Europe and the UK as well as regulatory authorization in Australia and New Zealand.
AVITA Medical has presented new clinical data showcasing the first documented use of its next-generation RECELL GO (搜索) automated autologous cell harvesting device in the United Kingdom, marking a significant milestone in the global adoption of the technology. The findings were presented at the 2026 British Burn Association Annual Meeting in Nottingham, U.K., and detailed outcomes from 17 patients treated at Stoke Mandeville Hospital across a range of burn and reconstructive surgery procedures.
The presentation, titled "First U.K. Clinical Experience of RECELL GO (搜索), an Automated Autologous Cell Harvesting Device, in Burn Surgery: A Case Series," evaluated the use of the automated system in patients selected based on injury characteristics and risk factors for healing complications, including larger and deeper wounds, facial injuries, and patients with higher Fitzpatrick skin types.
Clinical Outcomes and Workflow Benefits
In the case series, all 17 patients successfully received RECELL (搜索) Spray-On Skin Cells prepared using RECELL GO (搜索), either alone or in conjunction with meshed split-thickness skin grafts. Investigators reported uncomplicated donor-site healing, complete graft take, and successful patient discharge without complications across the entire cohort.
The authors highlighted notable workflow benefits associated with the automated system, including reduced procedural variability, improved consistency of cell preparation, and greater operating room efficiency. These findings suggest that RECELL GO (搜索) may help expand access to advanced autologous cell therapies by simplifying and standardizing preparation at the point of care, while preserving the clinical benefits associated with RECELL (搜索) treatment.
"RECELL GO (搜索) is an important next step in autologous cell harvesting technology," said Alexandra Atkins-Murray, Consultant Plastic and Burns Surgeon at Stoke Mandeville Hospital and senior author of the study. "Our early experience demonstrates that the automated system integrates seamlessly into clinical practice while maintaining the clinical outcomes we have come to expect from the RECELL (搜索) manual system. The ability to standardize preparation and free clinical staff during processing offers meaningful advantages for burn centers and surgical teams across the world."
Technology and Regulatory Progress
RECELL GO (搜索) combines a reusable, AC-powered RECELL (搜索) Processing Device with a single-use RECELL Preparation Kit to automate and standardize the preparation of RECELL Spray-On Skin Cells at the point of care. The system precisely regulates key processing steps to optimize consistency while reducing operator variability and training burden.
The device was CE-marked for commercialization in Europe and the U.K. in 2025 and has recently received regulatory authorization in Australia and New Zealand. In the U.K. and Ireland, RECELL GO (搜索) is distributed exclusively by Joint Operations Ltd (搜索). In the United States, RECELL (搜索) technology is FDA-approved for the treatment of thermal burn (搜索) and full-thickness skin defects.
Global Adoption Momentum
"The presentation of this first U.K. clinical experience marks another important milestone in the global adoption of RECELL GO (搜索)," said Cary Vance, President and Chief Executive Officer of AVITA Medical. "Clinicians are increasingly recognizing the value of technologies that can reduce donor-site burden, support healing, and improve workflow efficiency. We are encouraged by these early results from the U.K. and look forward to continuing to support burn centers worldwide as RECELL GO expands across Europe, the U.K., Australia, New Zealand, and other international markets."
The company also announced its participation at the Canaccord Genuity 46th Annual Growth Conference in Boston, taking place August 11–13, 2026, where President and CEO Cary Vance will speak on August 12. Additionally, AVITA Medical will report its second quarter 2026 financial results after the close of U.S. financial markets on August 6, 2026, followed by a conference call and webcast at 1:30 p.m. Pacific Time.
AVITA Medical's broader platform includes RECELL (搜索), which harnesses the healing properties of a patient's own skin to create Spray-On Skin Cells, as well as Cohealyx, a collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix, for which the company holds exclusive U.S. rights.